Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Haleos LabsBOM:540679 72 Days Inventory is 158.48 as of Mar. 2026, which is 28% above its 10-year median of 123.98. GuruFocus rates BOM:540679 with a GF Score™ of 72/100 and a GF Value™ of ₹1,129.71 (Significantly Overvalued). The stock has 10 warning signs investors should review. Among 638 Biotechnology companies, Haleos Labs ranks better than 63.79% on this metric.
Days Inventory is also known as Days Sales of Inventory (DSI). Haleos Labs's Average Total Inventories for the
three
months ended in Mar. 2026 was ₹798 Mil. Haleos Labs's Cost of Goods Sold for the
three
months ended in Mar. 2026 was ₹460 Mil.
Hence, Haleos Labs's Days Inventory for the
three
months ended in Mar. 2026 was 158.48.
The historical rank and industry rank for Haleos Labs's Days Inventory or its related term are showing as below:
BOM:540679'
s Days Inventory Range Over the Past 10 Years
Min: 77.71 Med: 123.98 Max: 146.36
Current: 128.23
During the past 11 years, Haleos Labs's highest Days Inventory was 146.36. The lowest was 77.71. And the median was 123.98.
BOM:540679's Days Inventory is ranked better than 63.79% of 638
companies
in the Biotechnology industry
Industry Median: 183.195
vs BOM:540679: 128.23
Haleos Labs's Days Inventory
increased
from Mar. 2025 (110.52) to Mar. 2026 (158.48).
It might indicate that Haleos Labs's sales slowed down.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Haleos Labs's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.58.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Haleos Labs's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 1.06.
Haleos Labs (BOM:540679) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Haleos Labs's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Haleos Labs's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Haleos Labs Days Inventory Related Terms
Haleos Labs Days Inventory Historical Data
* Premium members only.
The historical data trend for Haleos Labs's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:540679 vs VRTX, REGN, ALNY: Days Inventory Comparison
For the Biotechnology subindustry, Haleos Labs's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Haleos Labs Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Haleos Labs's Days Inventory distribution charts can be found below:
* The bar in red indicates where Haleos Labs's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Haleos Labs (BOM:540679) has a Days Inventory of 158.48 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Haleos Labs and its competitors. This is 28% above median its historical median of 123.98. Over the past decade, Haleos Labs' Days Inventory has ranged from 77.71 to 146.36. According to the industry distribution chart, Haleos Labs ranks #231 out of 638 companies in the Biotechnology industry, placing it in the top 36.2%.
Is Haleos Labs' Days Inventory too high?
Haleos Labs' current Days Inventory of 158.48 is 28% above median its 10-year median of 123.98. Over the past 10 years, this metric has ranged from a low of 77.71 to a high of 146.36. The Biotechnology industry median Days Inventory is 183.20. Haleos Labs' value of 158.48 is 13.5% below this industry median. Based on the distribution chart, Haleos Labs ranks #231 out of 638 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Haleos Labs has a GF Score™ of 72/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Haleos Labs' Days Inventory compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Haleos Labs ranks #231 out of 638 companies for Days Inventory. This puts Haleos Labs in the upper half of its industry. The industry median Days Inventory is 183.20. Haleos Labs' value of 158.48 is 13.5% below this benchmark. Historically, Haleos Labs' own Days Inventory has ranged from 77.71 to 146.36 over the past decade. While the company's 10-year median is 123.98 vs. the industry median of 183.20, Haleos Labs has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 183.20, based on 638 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Haleos Labs's current Days Inventory of 158.48 is 13.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Haleos Labs and its competitors. For the Biotechnology industry, the median Days Inventory is 183.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Haleos Labs's current Days Inventory is 158.48, which is 28% above median its own 10-year median of 123.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Haleos Labs stock overvalued right now?
Based on GuruFocus' analysis, Haleos Labs (BOM:540679) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹1,129.71, compared to a current price of ₹1,600.00 — trading 41.6% above its estimated fair value. The current Days Inventory is 158.48, which is 28% above median its 10-year median of 123.98 and 13.5% below the Biotechnology industry median of 183.20. Haleos Labs' overall GF Score™ is 72/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Haleos Labs (BOM:540679), the current Days Inventory is 158.48 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Haleos Labs (BOM:540679) Overvalued in 2026?
Based on GuruFocus' analysis, Haleos Labs stock appears to be overvalued.
The current stock price of ₹1,600.00 is trading 41.6% above its estimated GF Value™ of ₹1,129.71.
GuruFocus considers Haleos Labs to be Significantly Overvalued.
Key valuation signals for BOM:540679:
Days Inventory: 158.48 (28% above median its 10-year median of 123.98)
GF Value™: ₹1,129.71 vs. price of ₹1,600.00 (41.6% above fair value)
Industry Position: 13.5% below the Biotechnology median (#231 of 638)
No single metric tells the full story. See the BOM:540679 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Haleos Labs Ltd is engaged in the Business of manufacturing Active Pharmaceutical Ingredients (APIs) and its intermediates and sells its products in India as well as exports. The group sells its products in India and also exports it to other countries. Some of its API products are used in therapy as an Antiulcer, Antifungal, Anti Obesity, Anesthesia, and others. The company has manufacturing facilities at Kazipally and Jeedimetla and its Research and Development center at Sanatnagar in Hyderabad.
72GF Score
Get the complete analysis for BOM:540679
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:540679 has been successfully added to your 
